Pro-Inflammatory Immune Microenvironment and THBS1-Positive Monocytes as Drivers of Osteoclastogenesis in Postmenopausal Osteoporosis [0.03%]
绝经后骨质疏松症中促炎性免疫微环境和THBS1阳性单核细胞的破骨作用机制研究
Ming Li,Huanxin Sun,Liu Liu et al.
Ming Li et al.
Postmenopausal osteoporosis (PMOP) is driven by an imbalance in the interaction among osteoclasts, osteoblasts, and immune cells within the bone marrow microenvironment. However, detailed single-cell transcriptomic data on the bone microenv...
Denosumab-bbdz: A Review of the Interchangeable Biosimilar for the Treatment of Osteoporosis [0.03%]
关于抗骨质疏松药物地舒单抗生物类似药的综述文章
Kaitlyn North,Brandi Dahl,KariLynn Dowling-McClay et al.
Kaitlyn North et al.
In addition to other indications, it is a first-line option for postmenopausal osteoporosis with high or very high fracture risk after achieving equivalence in pharmacologic properties, safety, and markers for bone formation.
Overexpression of miR-671-3p alleviates postmenopausal osteoporosis by targeting GREM2 to activate BMP2/SMAD signaling pathway [0.03%]
miR-671-3p过表达通过靶向GREM2活化BMP2/SMAD信号通路缓解绝经后骨质疏松症
Yanlin Liang,Changqing Gu,Peng Wang et al.
Yanlin Liang et al.
Background: Increased fracture risk is linked to postmenopausal osteoporosis (PMOP), and elucidating the function of microRNAs (miRNAs) in this condition is vital for identifying individuals at high risk of fractures.
The rise and fall of raloxifene use for osteoporosis, 1999-2022 [0.03%]
1999年至2022年雷洛昔芬的兴起与衰落用于治疗骨质疏松症
Freddy F Shogry,Kaleen N Hayes,Sandra Kim et al.
Freddy F Shogry et al.
Purpose: Raloxifene has been available in Canada for postmenopausal osteoporosis since 1998. However, its benefit-to-risk ratio became questioned after evidence of increased risk of thrombosis and fatal stroke emerged in the early 2000s.
Picroside II regulates the YY1/TGFβ1 axis by inhibiting osteoblast ferroptosis to alleviate symptoms of postmenopausal osteoporosis [0.03%]
通过抑制成骨细胞铁死亡调节YY1/TGFβ1轴以缓解绝经后骨质疏松症状
Haoyu Wang,Jun Qian
Haoyu Wang
Picroside II (Pic II) has been used to treat many skeletal diseases. Postmenopausal osteoporosis (PMOP) is a serious skeletal disease that significantly threatens the health of postmenopausal women. We aimed to explore the roles and mechani...
Lobetyolin Suppressed Osteoclastogenesis and Alleviated Bone Loss in Ovariectomy-Induced Osteoporosis via Hindering p50/p65 Nuclear Translocation and Downstream NFATc1/c-Fos Expression [0.03%]
雷苔盐酸碱抑制卵巢切除诱导的骨质疏松小鼠破骨细胞分化并增加骨量：通过阻止p50/p65核转位及NFATc1/c-Fos表达实现
Chunmei Xiu,Hua Luo,Weixing Huang et al.
Chunmei Xiu et al.
Purpose: To investigate the therapeutic potential of lobetyolin (LBT), a bioactive compound derived from Codonopsis pilosula, against bone loss in postmenopausal osteoporosis (PMOP).
Integrin αVβ3 mediates estrogen to enhance osteoblast proliferation, differentiation, and alleviate OVX-induced postmenopausal osteoporosis [0.03%]
整合素αvβ3介导雌激素促进成骨细胞增殖、分化并缓解卵巢切除术后绝经后骨质疏松症的作用机制研究
Changshun Chen,Rongjing Chen,Jinyi Gu et al.
Changshun Chen et al.
Estrogen plays a critical role in maintaining bone homeostasis, and its deficiency leads to postmenopausal osteoporosis. This study investigated the role of integrin αVβ3 in estrogen-mediated osteoblast function and its therapeutic potent...
[Analysis of clinical characteristics and influencing factors of patients with postmenopausal osteoporosis combined with dyslipidemia] [0.03%]
绝经后骨质疏松症合并血脂异常患者的临床特征及影响因素分析
Rong Xie,Li-Guo Zhu,Zi-Kai Jin et al.
Rong Xie et al.
Objective: To explore the co-morbid influencing factors of postmenopausal osteoporosis(PMOP) and dyslipidemia, and to provide evidence-based basis for clinical co-morbidity management. ...
Serum asprosin and its association with bone mineral density, oxidative stress, and osteoprotegerin levels in Pakistani women with postmenopausal osteoporosis [0.03%]
人血清asprosin与氧化应激及骨保护素水平在绝经后巴基斯坦女性骨质疏松症患者中的相关性研究
Sampana Fatima,Muhammad Abrar,Adeela Shahid et al.
Sampana Fatima et al.
This study aimed to determine the role of asprosin in oxidative stress in postmenopausal osteoporosis and its relation with estrogen, osteoprotegerin (OPG), and bone mineral density (BMD)....The cutoff value of serum asprosin for screening postmenopausal osteoporosis by area under the curve was > 27.4 ng/ml with a sensitivity of 75% and a 1-specificity of 14%.
Self-Replenishable Metabolically Augmented Synbiotic Microspheres Remodel Gut-Bone Homeostasis [0.03%]
代谢增强的合生元微球重塑肠骨稳态
Zhijie Chen,Hua Liu,Yi Chen et al.
Zhijie Chen et al.
Gut microbiota dysbiosis in postmenopausal osteoporosis (PMO) is frequently accompanied by aberrant metabolism and absorption of short-chain fatty acids (SCFAs).
耗时 0.12986 秒，为您在
48229835
条记录里面共找到 3751 篇文章 [XML]